GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (NAS:ENVB) » Definitions » PE Ratio (TTM)

Enveric Biosciences (Enveric Biosciences) PE Ratio (TTM) : At Loss (As of May. 19, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Enveric Biosciences PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-05-19), Enveric Biosciences's share price is $0.84. Enveric Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.12. Therefore, Enveric Biosciences's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Enveric Biosciences's PE Ratio (TTM) or its related term are showing as below:

ENVB' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



ENVB's PE Ratio (TTM) is ranked worse than
100% of 248 companies
in the Biotechnology industry
Industry Median: 28.875 vs ENVB: At Loss

Enveric Biosciences's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-1.47. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.12.

As of today (2024-05-19), Enveric Biosciences's share price is $0.84. Enveric Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.44. Therefore, Enveric Biosciences's PE Ratio without NRI for today is At Loss.

During the past 13 years, Enveric Biosciences's highest PE Ratio without NRI was 482.04. The lowest was 0.00. And the median was 358.09.

Enveric Biosciences's EPS without NRI for the three months ended in Dec. 2023 was $-1.75. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.44.

During the past 3 years, the average EPS without NRI Growth Rate was 47.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 69.80% per year.

During the past 13 years, Enveric Biosciences's highest 3-Year average EPS without NRI Growth Rate was 97.00% per year. The lowest was -3001.20% per year. And the median was 53.60% per year.

Enveric Biosciences's EPS (Basic) for the three months ended in Dec. 2023 was $-1.47. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.12.


Enveric Biosciences PE Ratio (TTM) Historical Data

The historical data trend for Enveric Biosciences's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences PE Ratio (TTM) Chart

Enveric Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Enveric Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Enveric Biosciences's PE Ratio (TTM)

For the Biotechnology subindustry, Enveric Biosciences's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enveric Biosciences's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's PE Ratio (TTM) falls into.



Enveric Biosciences PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Enveric Biosciences's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.84/-8.120
=At Loss

Enveric Biosciences's Share Price of today is $0.84.
Enveric Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.12.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Enveric Biosciences  (NAS:ENVB) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Enveric Biosciences PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Enveric Biosciences (Enveric Biosciences) Business Description

Traded in Other Exchanges
Address
4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103
Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).
Executives
Frank Pasqualone director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kevin Michael Coveney officer: Chief Financial Officer 10 CLEVELAND ST, A, SOMERVILLE MA 02143-2606
Robert Iv Dickey officer: Chief Financial Officer 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bevin O'neil director C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103
Michael D Webb director C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Bradley George Thompson director 1646 ACTON AVE. SW, CALGARY, ALBERTA Z4 T2T 2P9
Jillian Marie Hagel officer: Chief Technical Officer 3655 36 ST NW, CALGARY, AB Z4 T2L 1Y8
Joseph Edward Tucker director, officer: Chief Executive Officer 3655 36 ST NW, CALGARY, AB, Z4 T2L 1Y8
Peter J. Facchini officer: Chief Scientific Officer 155 RANCHRIDGE DRIVE NW, CALGARY, ALBERTA Z4 T3G 1W1
Carter Julian Ward officer: Chief Financial Officer 165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Lind director
Marcus Schabacker director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Solomon Mayer director 150 CENTRAL PARK SOUTH 2ND FLOOR, NEW YORK NY 10019
David Ian Johnson director, officer: CEO and Chairman C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Robert G. Wilkins officer: Chief Medical Officer C/O JAY PHARMA INC., 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103

Enveric Biosciences (Enveric Biosciences) Headlines

From GuruFocus